This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
BACKGROUND AND PURPOSE: Feasibility of brain atrophy measurement in patients with MS in clinical routine, without prior standardization o...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Publication date: Available online 13 May 2017 Source: Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms Author(s): Ping Li...
-
Rejuvenation Research , Vol. 0, No. 0. from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2EFILxo via I...
-
Letter to the editor of Acta Neurochirurgica: simultaneous pericranial and nasoseptal "double-flap" reconstruction after comb...
-
Related Articles Characteristic MR Imaging Findings of the Neonatal Brain in RASopathies. AJNR Am J Neuroradiol. 2018 Apr 05;:...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου